<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Am Heart Assoc</journal-id><journal-id journal-id-type="iso-abbrev">J Am Heart Assoc</journal-id><journal-id journal-id-type="doi">10.1002/(ISSN)2047-9980</journal-id><journal-id journal-id-type="publisher-id">JAH3</journal-id><journal-id journal-id-type="hwp">ahaoa</journal-id><journal-title-group><journal-title>Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease</journal-title></journal-title-group><issn pub-type="epub">2047-9980</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26764413</article-id><article-id pub-id-type="pmc">4859385</article-id><article-id pub-id-type="doi">10.1161/JAHA.115.002674</article-id><article-id pub-id-type="publisher-id">JAH31274</article-id><article-categories><subj-group subj-group-type="overline"><subject>Original Research</subject></subj-group><subj-group subj-group-type="heading"><subject>Original Research</subject><subj-group subj-group-type="heading"><subject>Arrhythmia and Electrophysiology</subject></subj-group></subj-group></article-categories><title-group><article-title>Preserved Autonomic Cardiovascular Regulation With Cardiac Pacemaker Inhibition: A Crossover Trial Using High&#x02010;Fidelity Cardiovascular Phenotyping</article-title><alt-title alt-title-type="left-running-head">Heusser et&#x000a0;al</alt-title></title-group><contrib-group><contrib id="jah31274-cr-0001" contrib-type="author"><name><surname>Heusser</surname><given-names>Karsten</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="jah31274-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="jah31274-cr-0002" contrib-type="author"><name><surname>Tank</surname><given-names>Jens</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="jah31274-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="jah31274-cr-0003" contrib-type="author"><name><surname>Brinkmann</surname><given-names>Julia</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="jah31274-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="jah31274-cr-0004" contrib-type="author"><name><surname>Schroeder</surname><given-names>Christoph</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="jah31274-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="jah31274-cr-0005" contrib-type="author"><name><surname>May</surname><given-names>Marcus</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="jah31274-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="jah31274-cr-0006" contrib-type="author"><name><surname>Gro&#x000df;hennig</surname><given-names>Anika</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="jah31274-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="jah31274-cr-0007" contrib-type="author"><name><surname>Wenzel</surname><given-names>Daniela</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="jah31274-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="jah31274-cr-0008" contrib-type="author"><name><surname>Diedrich</surname><given-names>Andr&#x000e9;</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="jah31274-aff-0003">
<sup>3</sup>
</xref></contrib><contrib id="jah31274-cr-0009" contrib-type="author"><name><surname>Sweep</surname><given-names>Fred C. G. J.</given-names></name><degrees>MD, PhD</degrees><xref ref-type="aff" rid="jah31274-aff-0004">
<sup>4</sup>
</xref></contrib><contrib id="jah31274-cr-0010" contrib-type="author"><name><surname>Mehling</surname><given-names>Heidrun</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="jah31274-aff-0005">
<sup>5</sup>
</xref></contrib><contrib id="jah31274-cr-0011" contrib-type="author"><name><surname>Luft</surname><given-names>Friedrich C.</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="jah31274-aff-0005">
<sup>5</sup>
</xref></contrib><contrib id="jah31274-cr-0012" contrib-type="author" corresp="yes"><name><surname>Jordan</surname><given-names>Jens</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="jah31274-aff-0001">
<sup>1</sup>
</xref></contrib></contrib-group><aff id="jah31274-aff-0001"><label><sup>1</sup></label><named-content content-type="organisation-division">Institute of Clinical Pharmacology</named-content><institution>Hannover Medical School</institution><named-content content-type="city">Hannover</named-content><country country="DE">Germany</country></aff><aff id="jah31274-aff-0002"><label><sup>2</sup></label><named-content content-type="organisation-division">Institute of Biostatistics</named-content><institution>Hannover Medical School</institution><named-content content-type="city">Hannover</named-content><country country="DE">Germany</country></aff><aff id="jah31274-aff-0003"><label><sup>3</sup></label><named-content content-type="organisation-division">Division of Clinical Pharmacology</named-content><named-content content-type="organisation-division">Department of Medicine</named-content><named-content content-type="organisation-division">Autonomic Dysfunction Service</named-content><institution>Vanderbilt University</institution><named-content content-type="city">Nashville</named-content><named-content content-type="country-part">TN</named-content></aff><aff id="jah31274-aff-0004"><label><sup>4</sup></label><named-content content-type="organisation-division">Department of Laboratory Medicine</named-content><institution>Radboud University Medical Centre</institution><named-content content-type="city">Nijmegen</named-content><country country="NL">The Netherlands</country></aff><aff id="jah31274-aff-0005"><label><sup>5</sup></label><named-content content-type="organisation-division">Experimental Clinical Research Center</named-content><institution>Charit&#x000e9; Medical Faculty and Max Delbr&#x000fc;ck Center for Molecular Medicine</institution><named-content content-type="city">Berlin</named-content><country country="DE">Germany</country></aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence to:</bold> Jens Jordan, MD, Institute of Clinical Pharmacology, Hannover Medical School, Carl Neuberg Str. 1, 30625 Hannover, Germany. E&#x02010;mail: <email>jordan.jens@mh-hannover.de</email></corresp></author-notes><pub-date pub-type="epub"><day>13</day><month>1</month><year>2016</year></pub-date><pub-date pub-type="collection"><month>1</month><year>2016</year></pub-date><volume>5</volume><issue>1</issue><issue-id pub-id-type="doi">10.1002/jah3.2016.5.issue-1</issue-id><elocation-id>e002674</elocation-id><history><date date-type="received"><day>17</day><month>9</month><year>2015</year></date><date date-type="accepted"><day>03</day><month>12</month><year>2015</year></date></history><permissions><!--<copyright-statement content-type="issue-copyright"> Copyright &#x000a9; 2016 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley Blackwell <copyright-statement>--><copyright-statement content-type="article-copyright">&#x000a9; 2016 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley Blackwell.</copyright-statement><license license-type="creativeCommonsBy-nc"><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">Creative Commons Attribution&#x02010;NonCommercial</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.</license-p></license></permissions><self-uri content-type="pdf" xlink:type="simple" xlink:href="file:JAH3-5-e002674.pdf"/><abstract id="jah31274-abs-0001"><sec id="jah31274-sec-0001"><title>Background</title><p>Sympathetic and parasympathetic influences on heart rate (HR), which are governed by baroreflex mechanisms, are integrated at the cardiac sinus node through hyperpolarization&#x02010;activated cyclic nucleotide&#x02013;gated channels (HCN4). We hypothesized that HCN4 blockade with ivabradine selectively attenuates HR and baroreflex HR regulation, leaving baroreflex control of muscle sympathetic nerve activity intact.</p></sec><sec id="jah31274-sec-0002"><title>Methods and Results</title><p>We treated 21 healthy men with 2&#x000d7;7.5&#x000a0;mg ivabradine or placebo in a randomized crossover fashion. We recorded electrocardiogram, blood pressure, and muscle sympathetic nerve activity at rest and during pharmacological baroreflex testing. Ivabradine reduced normalized HR from 65.9&#x000b1;8.1 to 58.4&#x000b1;6.2&#x000a0;beats per minute (<italic>P</italic>&#x0003c;0.001) with unaffected blood pressure and muscle sympathetic nerve activity. On ivabradine, cardiac and sympathetic baroreflex gains and blood pressure responses to vasoactive drugs were unchanged. Ivabradine aggravated bradycardia during baroreflex loading.</p></sec><sec id="jah31274-sec-0003"><title>Conclusions</title><p>HCN4 blockade with ivabradine reduced HR, leaving physiological regulation of HR and muscle sympathetic nerve activity as well as baroreflex blood pressure buffering intact. Ivabradine could aggravate bradycardia during parasympathetic activation.</p></sec><sec id="jah31274-sec-0004"><title>Clinical Trial Registration</title><p>URL: <ext-link ext-link-type="uri" xlink:href="http://www.clinicaltrials.gov">http://www.clinicaltrials.gov</ext-link>. Unique identifier: NCT00865917.</p></sec></abstract><kwd-group kwd-group-type="author-generated"><kwd id="jah31274-kwd-0001">autonomic nervous system</kwd><kwd id="jah31274-kwd-0002">baroreflex control</kwd><kwd id="jah31274-kwd-0003">funny channel</kwd><kwd id="jah31274-kwd-0004">heart rate</kwd><kwd id="jah31274-kwd-0005">hemodynamics</kwd><kwd id="jah31274-kwd-0006">inhibitor</kwd><kwd id="jah31274-kwd-0007">microneurography</kwd><kwd id="jah31274-kwd-0008">pharmacology</kwd><kwd id="jah31274-kwd-0009">physiology</kwd><kwd id="jah31274-kwd-0010">sinoatrial node</kwd></kwd-group><kwd-group kwd-group-type="subject-categories"><title>Subject Categories</title><kwd>Autonomic Nervous System</kwd><kwd>Hemodynamics</kwd><kwd>Arrhythmias</kwd><kwd>Electrophysiology</kwd></kwd-group><funding-group><award-group><funding-source>German Research Foundation (Deutsche Forschungsgemeinschaft, DFG)</funding-source><award-id>JO 284/8&#x02010;1</award-id></award-group></funding-group><funding-group><award-group><funding-source>German Aerospace Center (Deutsches Zentrum f&#x000fc;r Luft&#x02010; und Raumfahrt, DLR</funding-source><award-id>50 WB1117</award-id></award-group></funding-group><counts><page-count count="9"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>component-id</meta-name><meta-value>jah31274</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>January 2016</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:4.8.9 mode:remove_FC converted:04.05.2016</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="jah31274-cit-1001">(<source>J Am Heart Assoc</source>. <year>2016</year>;<volume>5</volume>:e002674 doi: <ext-link ext-link-type="doi" xlink:href="10.1161/JAHA.115.002674">10.1161/JAHA.115.002674</ext-link>)</mixed-citation>
</p></notes></front><body><sec id="jah31274-sec-0005"><title>Introduction</title><p>Medication effects on human cardiovascular regulation are difficult to predict based on preclinical and clinical investigations. Drugs could interfere with cardiovascular regulation in brain or periphery directly or through secondary baroreflex&#x02010;mediated adjustments in heart rate (HR) and vascular tone. High&#x02010;fidelity phenotyping during infusion of vasoactive medications can be used to detect drug effects on human cardiovascular control that could otherwise go undetected. Ivabradine inhibits hyperpolarization&#x02010;activated cyclic nucleotide&#x02013;gated potassium channel 4 (HCN4). HCN4 generates &#x0201c;funny&#x0201d; pacemaker f currents (I<sub>f</sub>) promoting slow diastolic depolarization and cardiac rhythm generation.<xref rid="jah31274-bib-0001" ref-type="ref">1</xref> Intracellular cyclic adenosine monophosphate (cAMP) modulates I<sub>f</sub>
<xref rid="jah31274-bib-0002" ref-type="ref">2</xref>, and &#x003b2;&#x02010;adrenergic stimulation augments cAMP, thereby increasing HCN4 conductivity and HR. Cholinergic stimulation elicits the opposite response. Given HCN4's important role in autonomic HR adjustments, pharmacological HCN4 inhibition could profoundly affect human cardiovascular regulation. In fact, chronotropic competence is reduced<xref rid="jah31274-bib-0003" ref-type="ref">3</xref> or absent<xref rid="jah31274-bib-0004" ref-type="ref">4</xref> in mutated HCN4 channels unresponsive to cAMP. Conversely, blockade of HCN4 channels on baroreceptor sensory neurons increased their excitability,<xref rid="jah31274-bib-0005" ref-type="ref">5</xref>, <xref rid="jah31274-bib-0006" ref-type="ref">6</xref> which would tend to facilitate afferent baroreflex signaling and baroreflex function. The issue is relevant because ivabradine<xref rid="jah31274-bib-0007" ref-type="ref">7</xref>, <xref rid="jah31274-bib-0008" ref-type="ref">8</xref> is used in the treatment of heart failure<xref rid="jah31274-bib-0009" ref-type="ref">9</xref> and angina pectoris<xref rid="jah31274-bib-0010" ref-type="ref">10</xref>; however, the influences of HCN4 on human cardiovascular autonomic regulation have not been studied, aside from noninvasive baroreflex assessment of profound sympathetic activation.<xref rid="jah31274-bib-0011" ref-type="ref">11</xref> Ivabradine is an open&#x02010;channel blocker<xref rid="jah31274-bib-0012" ref-type="ref">12</xref> producing &#x0201c;frequency&#x02010;dependent&#x0201d; or &#x0201c;use&#x02010;dependent&#x0201d; HCN4 inhibition,<xref rid="jah31274-bib-0013" ref-type="ref">13</xref> thus ivabradine may be more effective at increased HR.<xref rid="jah31274-bib-0014" ref-type="ref">14</xref> We tested the hypothesis that pharmacological HCN4 blockade with ivabradine affects baroreflex HR regulation in healthy participants such that HR is reduced at a given blood pressure (BP). Moreover, we assessed whether ivabradine would interfere with baroreflex regulation of HR and sympathetic efferent traffic to resistance vessels and whether or not baroreflex BP buffering is perturbed. Finally, we evaluated whether or not in&#x000a0;vivo responses mirror ivabradine's use&#x02010;dependent pharmacology.</p></sec><sec id="jah31274-sec-0006"><title>Methods</title><sec id="jah31274-sec-0007"><title>Participants</title><p>Healthy men (aged 18&#x02013;40&#x000a0;years) with a body mass index between 18 and 30&#x000a0;kg/m<sup>2</sup> and a resting HR &#x02265;60&#x000a0;beats per minute (bpm) were eligible for this study. Preexisting diseases were ruled out through a detailed history, medical examination, 12&#x02010;lead ECG, BP recordings, and blood sampling for routine laboratory measurements. All procedures were in accordance with the Helsinki Declaration of 1975 (as revised in 1983). A national competent authority and the local internal review board approved the studies. Written informed consent was obtained before inclusion.</p></sec><sec id="jah31274-sec-0008"><title>Study Design and Protocol</title><p>This randomized, double&#x02010;blind, 2&#x02010;period, 2&#x02010;sequence, crossover study was conducted at 2 sites (Experimental Clinical Research Center, Charit&#x000e9; Medical University, Berlin, Germany, and Institute of Clinical Pharmacology, Hannover Medical School, Hannover, Germany). Randomization for study drug sequence (randomization block size: 6) and manufacturing and labeling of blinded medications was done centrally by the pharmacy of the Charit&#x000e9; Medical University. Medications were prepared as identical capsules in neutral containers labeled with the randomization code and a visit identifier. After inclusion, participants were consecutively allocated to the next available randomization number. Adherence to randomized medication sequence was secured by following the predefined numeric sequence of the visits. Consequently, participants and investigators remained fully blinded until the database had been locked, double checked, and transferred to the Institute of Biostatistics at Hannover Medical School. The study was registered at ClinicalTrials.gov (identifier NCT00865917).</p><p>On 2 separate occasions, participants ingested maximally recommended doses of ivabradine (7.5&#x000a0;mg) or matching placebo 13 hours and 1&#x000a0;hour before testing. The washout period between study days was at least 3&#x000a0;weeks. Testing was conducted between 8 and 11&#x000a0;<sc>am</sc> in a quiet laboratory at an ambient temperature of 22 to 23&#x000b0;C.</p><p>An ECG was continuously recorded (Niccomo, Medis GmbH) for HR determination. Recumbent systolic BP (SBP), mean BP, and diastolic arterial BP were measured with an automated oscillometric device (Dinamap; GE/Critikon). We obtained blood samples after at least 30&#x000a0;minutes of rest for plasma catecholamine determination with high&#x02010;pressure liquid chromatography and consecutive electrochemical detection.<xref rid="jah31274-bib-0015" ref-type="ref">15</xref> Stroke volume and cardiac output were obtained using an inert gas rebreathing technique (Innocor; Innovision). Muscle sympathetic nerve activity (MSNA) was recorded from the right peroneal nerve (Nerve Traffic Analyzer 662C&#x02010;3; Biomedical Engineering Department, University of Iowa, Iowa City, IA), as described previously.<xref rid="jah31274-bib-0016" ref-type="ref">16</xref> Data were analog&#x02010;to&#x02010;digital converted and analyzed using a program written by one of the authors (A.D.). We determined the following MSNA parameters from the integrated nerve signal: burst frequency, or the number of MSNA bursts per minute; burst incidence, or the number of bursts per 100 heart beats; and total activity, or the area under the bursts per minute as arbitrary units per minute.</p><p>Following a resting period of at least 30&#x000a0;minutes, we obtained resting baseline recordings in the supine position. After taking blood samples and measuring cardiac output, we performed a pharmacological baroreflex assessment using the nitric oxide donor sodium nitroprusside (vasodilator) and the &#x003b1;1&#x02010;adrenoceptor agonist phenylephrine (vasoconstrictor). Incremental infusions were given over periods of 6&#x000a0;minutes per dose step. Dose incrementation was stopped after the maximum dose of 2.1&#x000a0;&#x003bc;g/kg per minute had been reached, SBP had changed by &#x0003e;25&#x000a0;mm&#x000a0;Hg, or HR had dropped &#x0003c;40&#x000a0;bpm.</p></sec><sec id="jah31274-sec-0009"><title>End Points</title><p>Main end points of the study were normalized HR (ie, HR at a given BP) and resting MSNA burst frequency during supine rest. Exploratory end points served to further characterize hemodynamic and autonomic responses to ivabradine at rest and during pharmacologic baroreflex challenge: arterial BP, stroke volume, cardiac output, total peripheral resistance, plasma catecholamine levels, cardiac and sympathetic baroreflex characteristics, and vasoactor sensitivity. The latter was defined as SBP change per dose increment of sodium nitroprusside and phenylephrine, respectively.</p></sec><sec id="jah31274-sec-0010"><title>HR Normalization</title><p>Ivabradine is expected to change HR directly, but it may do so also indirectly via baroreflexes through changes in BP. To remove confounding baroreflex influences on resting HR, we normalized HR before data unblinding (example in Figure&#x000a0;<xref rid="jah31274-fig-0001" ref-type="fig">1</xref>): We transferred the relationship between RR intervals (RRIs) and corresponding SBP values during pharmacological baroreflex testing into a mathematical function by linear regression or baroreflex curve fitting using a Boltzmann sigmoidal function separately for the placebo and ivabradine condition for each participant (sigmoidal curves in the example). Resting SBP of both visits (vertical dotted lines in the Figure&#x000a0;1) were averaged. The average served as shared common (standard) pressure (vertical solid line in the figure). This standard pressure was used as input (abscissa value) to the baroreflex curve function to calculate normalized RRI and HR for each visit separately (ordinate values).</p><fig fig-type="Figure" xml:lang="en" id="jah31274-fig-0001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>
<styled-content style="fixed-case">HR</styled-content> normalization procedure. The example assumes lower <styled-content style="fixed-case">SBP</styled-content> on ivabradine than on placebo (118&#x000a0;vs 122&#x000a0;mm&#x000a0;Hg). Related <styled-content style="fixed-case">RR</styled-content>Is are labeled &#x0201c;raw <styled-content style="fixed-case">RRI.</styled-content>&#x0201d; The solid vertical line represents mean <styled-content style="fixed-case">SBP</styled-content> (120&#x000a0;mm&#x000a0;Hg), which determines &#x0201c;normalized <styled-content style="fixed-case">RRI</styled-content>&#x0201d; values. Without normalization, ivabradine's effect on <styled-content style="fixed-case">HR</styled-content> would have been underestimated, as demonstrated by the smaller difference between the 2 raw <styled-content style="fixed-case">RRI</styled-content> values compared with the normalized <styled-content style="fixed-case">RRI</styled-content> values. HR indicates heart rate; RRI, RR interval; SBP, systolic blood pressure.</p></caption><graphic id="nlm-graphic-1" xlink:href="JAH3-5-e002674-g001"/></fig></sec><sec id="jah31274-sec-0011"><title>Merged Baroreflex Curves</title><p>Baroreflex&#x02010;mediated changes in the dependent parameters (MSNA, RRI) were collected in 10&#x02010;mm&#x000a0;Hg bins separately for placebo and ivabradine. Related bins for all participants were merged. Using GraphPad Prism 5, a Boltzmann sigmoidal function was fitted to these merged data, and 95% confidence bands were calculated and plotted. Note that the bins for lowest and highest BP are least occupied by values, thus their weight in calculations of curve&#x02010;fitting parameters and confidence bands are small (Figure&#x000a0;6A and 6B).</p></sec><sec id="jah31274-sec-0012"><title>Statistics</title><p>We expected to observe an ivabradine&#x02010;related HR reduction by &#x02248;6&#x000a0;bpm. With SD of 6.7&#x000a0;bpm in the group's resting HR paired differences, &#x003b1;=0.05, and 2&#x02010;sided testing, 15 participants would provide &#x02265;80% statistical power to detect such a difference.<xref rid="jah31274-bib-0017" ref-type="ref">17</xref> We included additional participants to allow for the meaningful analysis of secondary and exploratory end points. According to a prospective data analysis plan, primary and secondary end points were analyzed using the Hills&#x02010;Armitage approach.<xref rid="jah31274-bib-0018" ref-type="ref">18</xref> The method allows period&#x02010;adjusted therapy effect estimation, namely, calculation of period&#x02010;adjusted <italic>P</italic> values for mean differences between placebo and ivabradine data. To appreciate consistency of the results, several sensitivity analyses were performed (univariate 1&#x02010;sample <italic>t</italic> tests and mixed&#x02010;model analysis with participant as random effect). Exploratory variables have been tested with <italic>t</italic> tests for paired data and correlation analysis without adjustments for multiple testing. A&#x000a0;value of <italic>P</italic>&#x0003c;0.05 was considered significant. If not otherwise indicated, data are expressed as mean&#x000b1;SD.</p></sec></sec><sec id="jah31274-sec-0013"><title>Results</title><p>We screened 26 men: 23 met inclusion and exclusion criteria and entered the study. Twenty&#x02010;one men completed both study visits (2 dropped out) (Figure&#x000a0;<xref rid="jah31274-fig-0002" ref-type="fig">2</xref>). Microneurographic recordings were obtained in 18 participants on both days. In 3 participants, we failed to obtain a stable nerve recording position at the second experimental day. The characteristics of the participants were as follows: age 26.8&#x000b1;4.2&#x000a0;years, height 1.82&#x000b1;0.06&#x000a0;m, body mass 79.8&#x000b1;10.5&#x000a0;kg, body mass index 24.1&#x000b1;3.0&#x000a0;kg/m<sup>2</sup>, BP 130&#x000b1;8/72&#x000b1;8&#x000a0;mm&#x000a0;Hg, and HR 67.4&#x000b1;5.8&#x000a0;bpm. Two adverse events (insomnia, hyperhidrosis) occurred during the study. The events were not judged to be related to the study medication. There were no serious adverse events.</p><fig fig-type="Figure" xml:lang="en" id="jah31274-fig-0002" orientation="portrait" position="float"><label>Figure 2</label><caption><p>
<styled-content style="fixed-case">CONSORT</styled-content> flow diagram of participant enrollment, allocation, and analysis. IC indicates informed consent; IVA, ivabradine; PLC, placebo</p></caption><graphic id="nlm-graphic-3" xlink:href="JAH3-5-e002674-g002"/></fig><p>Experimental data are shown in <xref rid="jah31274-tbl-0001" ref-type="table-wrap">Table</xref>. I<sub>f</sub> blockade reduced resting HR with and without normalization for prevailing BP (Figure&#x000a0;<xref rid="jah31274-fig-0003" ref-type="fig">3</xref>A) (for HR normalization, see <xref rid="jah31274-sec-0002" ref-type="sec">Methods</xref>). Ivabradine did not influence resting MSNA (Figure&#x000a0;<xref rid="jah31274-fig-0004" ref-type="fig">4</xref>). BP and stroke volume remained unchanged with a trend toward reduced cardiac output (&#x02248;7.6%) and increased total peripheral resistance (&#x02248;5.6%) on ivabradine. Plasma catecholamine levels were similar under both conditions. SBP sensitivity to sodium nitroprusside infusion was similar on both study days with a trend toward reduced sensitivity (improved BP buffering) to the vasoconstrictor phenylephrine with I<sub>f</sub> blockade (Figure&#x000a0;<xref rid="jah31274-fig-0005" ref-type="fig">5</xref>). Ivabradine did not alter pharmacological baroreflex sensitivities, such as the cardiac parasympathetic and vasoconstrictor sympathetic baroreflex gains. I<sub>f</sub> blockade dampens the increase in MSNA burst frequency during higher sodium nitroprusside infusion rates, namely, when high vasoconstrictor activity and elevated HR co&#x02010;occur (Figure&#x000a0;<xref rid="jah31274-fig-0006" ref-type="fig">6</xref>A); however, HR&#x02010;independent MSNA parameters (ie, MSNA burst incidence and total activity) were not altered by HCN4 blockade during pharmacological baroreflex testing (data not shown). Ivabradine caused a &#x0201c;parallel&#x0201d; upward shift of the cardiac baroreflex curve to longer RRIs (Figure&#x000a0;<xref rid="jah31274-fig-0006" ref-type="fig">6</xref>B). Consequently, RRI lengthening by ivabradine was virtually independent of the prevailing HR during pharmacological baroreflex testing.</p><table-wrap id="jah31274-tbl-0001" xml:lang="en" orientation="portrait" position="float"><label>Table 1</label><caption><p>Hemodynamic, Sympathetic, Hormonal, and Baroreflex Parameters</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1">Parameter</th><th align="left" valign="top" rowspan="1" colspan="1">Placebo</th><th align="left" valign="top" rowspan="1" colspan="1">Ivabradine</th><th align="left" valign="top" rowspan="1" colspan="1">
<italic>P</italic> Value</th></tr></thead><tbody><tr><td align="left" colspan="4" rowspan="1">Hemodynamics</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">HR, bpm</td><td align="left" rowspan="1" colspan="1">65.9&#x000b1;8.1</td><td align="left" rowspan="1" colspan="1">58.4&#x000b1;6.2</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">HR<sub>P</sub>, bpm</td><td align="left" rowspan="1" colspan="1">52.7&#x000b1;7.4</td><td align="left" rowspan="1" colspan="1">47.3&#x000b1;5.5</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.002</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">SBP, mm&#x000a0;Hg</td><td align="left" rowspan="1" colspan="1">123&#x000b1;8</td><td align="left" rowspan="1" colspan="1">122&#x000b1;8</td><td align="left" rowspan="1" colspan="1">0.649</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">MBP, mm&#x000a0;Hg</td><td align="left" rowspan="1" colspan="1">89&#x000b1;4</td><td align="left" rowspan="1" colspan="1">89&#x000b1;4</td><td align="left" rowspan="1" colspan="1">0.894</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">DBP, mm&#x000a0;Hg</td><td align="left" rowspan="1" colspan="1">68&#x000b1;5</td><td align="left" rowspan="1" colspan="1">69&#x000b1;5</td><td align="left" rowspan="1" colspan="1">0.582</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">CO, L/min</td><td align="left" rowspan="1" colspan="1">7.74&#x000b1;1.60</td><td align="left" rowspan="1" colspan="1">7.19&#x000b1;1.15</td><td align="left" rowspan="1" colspan="1">0.071</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">SV, mL</td><td align="left" rowspan="1" colspan="1">118&#x000b1;23</td><td align="left" rowspan="1" colspan="1">118&#x000b1;18</td><td align="left" rowspan="1" colspan="1">0.899</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">TPR, dyn&#x000b7;s/cm<sup>5</sup>
</td><td align="left" rowspan="1" colspan="1">956&#x000b1;185</td><td align="left" rowspan="1" colspan="1">1010&#x000b1;160</td><td align="left" rowspan="1" colspan="1">0.088</td></tr><tr><td align="left" colspan="4" rowspan="1">Sympathetic activity (MSNA bursts)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Frequency, bursts/min</td><td align="left" rowspan="1" colspan="1">28.4&#x000b1;7.9</td><td align="left" rowspan="1" colspan="1">26.2&#x000b1;6.7</td><td align="left" rowspan="1" colspan="1">0.221</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Incidence, bursts/100 heart beats</td><td align="left" rowspan="1" colspan="1">46.0&#x000b1;11.3</td><td align="left" rowspan="1" colspan="1">45.3&#x000b1;12.1</td><td align="left" rowspan="1" colspan="1">0.575</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Total activity, au</td><td align="left" rowspan="1" colspan="1">1.14&#x000b1;0.45</td><td align="left" rowspan="1" colspan="1">1.26&#x000b1;0.76</td><td align="left" rowspan="1" colspan="1">0.892</td></tr><tr><td align="left" colspan="4" rowspan="1">Hormones</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Dopamine, pmol/L</td><td align="left" rowspan="1" colspan="1">69&#x000b1;25</td><td align="left" rowspan="1" colspan="1">70&#x000b1;14</td><td align="left" rowspan="1" colspan="1">0.520</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Norepinephrine, pmol/L</td><td align="left" rowspan="1" colspan="1">1040&#x000b1;500</td><td align="left" rowspan="1" colspan="1">910&#x000b1;210</td><td align="left" rowspan="1" colspan="1">0.654</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Epinephrine, pmol/L</td><td align="left" rowspan="1" colspan="1">135&#x000b1;84</td><td align="left" rowspan="1" colspan="1">132&#x000b1;64</td><td align="left" rowspan="1" colspan="1">0.553</td></tr><tr><td align="left" colspan="4" rowspan="1">Pharmacological baroreflex and vasoactor sensitivity</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Cardiac BRG, ms/mm&#x000a0;Hg</td><td align="left" rowspan="1" colspan="1">16.8&#x000b1;8.4</td><td align="left" rowspan="1" colspan="1">14.8&#x000b1;6.5</td><td align="left" rowspan="1" colspan="1">0.151</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Sympathetic BRG, bursts/min/mm&#x000a0;Hg</td><td align="left" rowspan="1" colspan="1">&#x02212;2.74&#x000b1;1.07</td><td align="left" rowspan="1" colspan="1">&#x02212;2.53&#x000b1;0.83</td><td align="left" rowspan="1" colspan="1">0.247</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">NTP sensitivity, mm Hg &#x003bc;g<sup>&#x02212;1</sup> min<sup>&#x02212;1</sup> kg<sup>&#x02212;1</sup>
</td><td align="left" rowspan="1" colspan="1">&#x02212;7.9&#x000b1;6.4</td><td align="left" rowspan="1" colspan="1">&#x02212;6.2&#x000b1;4.6</td><td align="left" rowspan="1" colspan="1">0.158</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">PHE sensitivity, mm Hg &#x003bc;g<sup>&#x02212;1</sup> min<sup>&#x02212;1</sup> kg<sup>&#x02212;1</sup>
</td><td align="left" rowspan="1" colspan="1">20.5&#x000b1;8.0</td><td align="left" rowspan="1" colspan="1">18.0&#x000b1;6.3</td><td align="left" rowspan="1" colspan="1">0.073</td></tr></tbody></table><table-wrap-foot><fn id="jah31274-note-0001"><p>au indicates arbitrary units; BRG, baroreflex gain (ie, baroreflex sensitivity); CO, cardiac output; DBP, diastolic blood pressure; HR, normalized (baroreflex&#x02010;corrected) heart rate; HR<sub>P</sub>, normalized heart rate during parasympathetic activation; MBP, mean blood pressure; MSNA, muscle sympathetic nerve activity; NTP, sodium nitroprusside; PHE, phenylephrine; SBP, systolic blood pressure; SV, stroke volume; TPR, total peripheral resistance.</p></fn></table-wrap-foot></table-wrap><fig fig-type="Figure" xml:lang="en" id="jah31274-fig-0003" orientation="portrait" position="float"><label>Figure 3</label><caption><p>Individual effects of <styled-content style="fixed-case">HCN</styled-content>4 inhibition on <styled-content style="fixed-case">HR</styled-content>. A, Effects of <styled-content style="fixed-case">HCN</styled-content>4 inhibition on resting <styled-content style="fixed-case">HR</styled-content>. Solid and dashed lines denote <styled-content style="fixed-case">HR</styled-content> decreases and increases, respectively. B, Ivabradine's use dependence: <styled-content style="fixed-case">HR</styled-content> lowering is more pronounced in participants with higher resting <styled-content style="fixed-case">HR</styled-content>. With resting values of &#x02248;56.5&#x000a0;bpm, ivabradine has no effect (unresponsive <styled-content style="fixed-case">HR</styled-content>). C, Effects of <styled-content style="fixed-case">HCN</styled-content>4 inhibition on <styled-content style="fixed-case">HR</styled-content> during parasympathetic activation (<styled-content style="fixed-case">HR<sub>P</sub></styled-content>) through baroreflex loading with phenylephrine. <styled-content style="fixed-case">HR<sub>P</sub></styled-content> was assessed as <styled-content style="fixed-case">HR</styled-content> at the largest individual phenylephrine dose that was reached on both study days. Solid and dashed lines denote <styled-content style="fixed-case">HR<sub>P</sub></styled-content> decreases and increases, respectively. D, Participants with lower <styled-content style="fixed-case">HR<sub>P</sub></styled-content> on placebo exhibited a smaller reduction in <styled-content style="fixed-case">HR<sub>P</sub></styled-content> with ivabradine. The observation is consistent with ivabradine's use&#x02010;dependent pharmacology; however, parasympathetic activation shifted the unresponsive <styled-content style="fixed-case">HR</styled-content> to &#x02248;44.2&#x000a0;bpm, which is &#x02248;12&#x000a0;bpm lower compared with resting conditions (see panel B). bpm indicates beats per minute; HR, heart rate.</p></caption><graphic id="nlm-graphic-5" xlink:href="JAH3-5-e002674-g003"/></fig><fig fig-type="Figure" xml:lang="en" id="jah31274-fig-0004" orientation="portrait" position="float"><label>Figure 4</label><caption><p>Effects of <styled-content style="fixed-case">HCN</styled-content>4 inhibition on <styled-content style="fixed-case">MSNA</styled-content>. A, Original recordings of 2 participants. B, Individual changes in <styled-content style="fixed-case">MSNA</styled-content> burst frequency, burst incidence, and total <styled-content style="fixed-case">MSNA</styled-content> by ivabradine compared with placebo. Total <styled-content style="fixed-case">MSNA</styled-content> has been rescaled (&#x000d7;20) for visual range harmonization among the 3 <styled-content style="fixed-case">MSNA</styled-content> measures (also see Table). au indicates arbitrary units; hb, heart beats; MSNA, muscle sympathetic nerve activity. </p></caption><graphic id="nlm-graphic-7" xlink:href="JAH3-5-e002674-g004"/></fig><fig fig-type="Figure" xml:lang="en" id="jah31274-fig-0005" orientation="portrait" position="float"><label>Figure 5</label><caption><p>
<styled-content style="fixed-case">BP</styled-content> sensitivity to vasoactors. Effects of <styled-content style="fixed-case">HCN</styled-content>4 inhibition on <styled-content style="fixed-case">BP</styled-content> sensitivity to infusion of the vasoconstrictor phenylephrine&#x000a0;(upper panel) and the vasodilator sodium nitroprusside&#x000a0;(lower panel) during placebo (open circles) and ivabradine (closed circles).&#x000a0;Note the trend toward improved baroreflex buffering of <styled-content style="fixed-case">BP</styled-content> increases on ivabradine (upper panel). BP indicates blood pressure. </p></caption><graphic id="nlm-graphic-9" xlink:href="JAH3-5-e002674-g005"/></fig><fig fig-type="Figure" xml:lang="en" id="jah31274-fig-0006" orientation="portrait" position="float"><label>Figure 6</label><caption><p>Interactions between ivabradine and arterial baroreflexes. A, Sympathetic baroreflex: Although ivabradine may dampen the increase in <styled-content style="fixed-case">MSNA</styled-content> burst frequency during nitroprusside infusion (ie, when high vasoconstrictor activity and elevated HR co&#x02010;occur), baroreflex curves are virtually identical if <styled-content style="fixed-case">HR</styled-content>&#x02010;independent <styled-content style="fixed-case">MSNA</styled-content> measures (burst incidence and total activity) are used (curves not shown). B, Cardiac baroreflex: Ivabradine shifts (&#x0201c;offsets&#x0201d;) the baroreflex curve upward (to longer <styled-content style="fixed-case">RR</styled-content>Is) with virtually no effect on slope or range. Shaded areas indicate 95% confidence bands. Note that the bands do not overlap with high blood pressure, indicating that baroreflex&#x02010;mediated <styled-content style="fixed-case">HR</styled-content> slowing is intensified by ivabradine. DBP indicates diastolic blood pressure; HR, heart rate; MSNA, muscle sympathetic nerve activity; RRI, RR interval; SBP, systolic blood pressure.</p></caption><graphic id="nlm-graphic-11" xlink:href="JAH3-5-e002674-g006"/></fig><p>Participants with higher resting HR on placebo exhibited more pronounced HR slowing on ivabradine, showing &#x0201c;use dependence&#x0201d; (Figure&#x000a0;<xref rid="jah31274-fig-0003" ref-type="fig">3</xref>B). Participants with HR below &#x02248;56.5&#x000a0;bpm did not respond to I<sub>f</sub> blockade. We observed a similar pattern during baroreflex loading with phenylephrine (Figure&#x000a0;<xref rid="jah31274-fig-0003" ref-type="fig">3</xref>C and <xref rid="jah31274-fig-0003" ref-type="fig">3</xref>D); however, the HR at which ivabradine did not slow HR further was only &#x02248;44.2&#x000a0;bpm (ie, &#x02248;12&#x000a0;bpm lower during parasympathetic activation). Together, Figure&#x000a0;<xref rid="jah31274-fig-0003" ref-type="fig">3</xref>B and <xref rid="jah31274-fig-0003" ref-type="fig">3</xref>D visualize ivabradine's use&#x02010;dependent characteristics; however, they also show, as does Figure&#x000a0;<xref rid="jah31274-fig-0006" ref-type="fig">6</xref>B, that ivabradine and parasympathetic activation are additive in terms of HR reduction.</p></sec><sec id="jah31274-sec-0014"><title>Discussion</title><p>We observed that HCN4 blockade with ivabradine reduces HR, leaving baroreflex HR and MSNA regulation intact. Although HCN4 is involved in transducing autonomic activity at the sinus node level, baroreflex HR regulation was preserved on ivabradine. The cardiac baroreflex curve was parallel&#x02010;shifted toward lower HR without reductions in baroreflex gain or range. Similarly, baroreflex HR slopes determined noninvasively by cross&#x02010;spectral analysis or the sequence method were unchanged with ivabradine in a human model of cardiac sympathetic activation.<xref rid="jah31274-bib-0011" ref-type="ref">11</xref> Because MSNA discharges occur during diastole when arterial baroreceptors are unloaded, we expected reduced MSNA frequencies with compensatory increases in sympathetic action potentials within bursts; however, ivabradine&#x02010;induced HR reduction was not associated with resting MSNA changes. Moreover, sympathetic baroreflex regulation was virtually identical on placebo and on ivabradine considering HR&#x02010;independent MSNA measurements. Finally, BP responses to vasoactive medications did not increase on ivabradine, suggesting that baroreflex BP buffering remained fully functional.<xref rid="jah31274-bib-0019" ref-type="ref">19</xref>
</p><p>Together with previous studies in genetic animal models and in patients with familial sinus bradycardia due to HCN4 mutations,<xref rid="jah31274-bib-0003" ref-type="ref">3</xref>, <xref rid="jah31274-bib-0020" ref-type="ref">20</xref>, <xref rid="jah31274-bib-0021" ref-type="ref">21</xref>, <xref rid="jah31274-bib-0022" ref-type="ref">22</xref>, <xref rid="jah31274-bib-0023" ref-type="ref">23</xref> our study provides new insight into HCN4's role in HR regulation. In patients with the 573X mutation, HCN4 does not respond to cAMP.<xref rid="jah31274-bib-0003" ref-type="ref">3</xref> Nevertheless, HR increased &#x02248;50&#x000a0;bpm during exercise. Likewise, HR acceleration to &#x003b2;&#x02010;adrenoreceptor stimulation was intact in adult HCN4&#x02010;deleted mice<xref rid="jah31274-bib-0024" ref-type="ref">24</xref> and in a heterozygous knock&#x02010;in model rendering HCN4 cAMP insensitive.<xref rid="jah31274-bib-0004" ref-type="ref">4</xref> On ivabradine, chronotropic competence in terms of HR acceleration and deceleration over a wide HR range assessed through baroreflex loading and unloading was unchanged. Consequently, I<sub>f</sub> cannot be the crucial mechanism transducing autonomic signals at the level of the sinus node.</p><p>Cardiac pacemaker models are composed of several clocks,<xref rid="jah31274-bib-0025" ref-type="ref">25</xref>, <xref rid="jah31274-bib-0026" ref-type="ref">26</xref> raising questions about HCN4's dominant role in sinoatrial node automatism and rate regulation. Instead, HCN4 may defend the sinus node against excess hyperpolarization,<xref rid="jah31274-bib-0027" ref-type="ref">27</xref> preventing bradycardia. Despite its use&#x02010;dependent pharmacology,<xref rid="jah31274-bib-0012" ref-type="ref">12</xref> indicated by larger HR reduction in persons with higher resting HR, ivabradine aggravated baroreflex&#x02010;mediated bradycardia in our study. Moreover, in the SIGNIFY study, almost 10 000 patients with stable coronary artery disease received ivabradine doses up to 10&#x000a0;mg twice daily. Bradycardia and atrial fibrillation occurred more often in the ivabradine group.<xref rid="jah31274-bib-0028" ref-type="ref">28</xref> Together with our mechanism&#x02010;oriented study, these observations translate the preclinical concept that I<sub>f</sub> is a defense mechanism against excess bradycardia to humans. Using a similar approach, we previously observed that &#x003b1;2&#x02010;adrenoreceptor stimulation with clonidine also disables physiological safeguards maintaining HR.<xref rid="jah31274-bib-0029" ref-type="ref">29</xref>
</p><p>Our study has potential limitations. We did not investigate responses to ivabradine under steady state conditions; however, we showed earlier that acute dosing 13 hours and 1&#x000a0;hour before measurements was sufficient to attain ivabradine plasma concentrations in a therapeutic range.<xref rid="jah31274-bib-0011" ref-type="ref">11</xref> Furthermore, the drug's bradycardic activity consists of an initial rapid and subsequent relatively long duration of action caused by the N&#x02010;dealkylated metabolite and the parent drug, respectively.<xref rid="jah31274-bib-0030" ref-type="ref">30</xref> On the other hand, the 3&#x02010;week washout period was more than twice the time required to avoid carryover, according to the kinetics of the bradycardic effect with repeated oral administration.<xref rid="jah31274-bib-0030" ref-type="ref">30</xref> Ivabradine's pharmacological interaction with HCN4 channels complicates the interpretation of our study. As an open&#x02010;channel blocker, for example, ivabradine features use dependence with trapping of the drug in the closed HCN4 channel.<xref rid="jah31274-bib-0008" ref-type="ref">8</xref> Furthermore, HCN4 is also expressed in the nervous system, particularly in the thalamus,<xref rid="jah31274-bib-0031" ref-type="ref">31</xref> in spinal interneurons,<xref rid="jah31274-bib-0032" ref-type="ref">32</xref> and in baroreflex afferents.<xref rid="jah31274-bib-0005" ref-type="ref">5</xref>, <xref rid="jah31274-bib-0006" ref-type="ref">6</xref> MSNA is a sensitive readout for changes in central autonomic regulation.<xref rid="jah31274-bib-0033" ref-type="ref">33</xref>, <xref rid="jah31274-bib-0034" ref-type="ref">34</xref>, <xref rid="jah31274-bib-0035" ref-type="ref">35</xref> Because MSNA did not change, confounding effects by neural HCN4 inhibition is unlikely; however, diseases could alter the ivabradine response. Blunted baroreflex function in type 1 diabetic rats, for example, was associated with increased HCN expression and cAMP sensitivity.<xref rid="jah31274-bib-0006" ref-type="ref">6</xref> Our findings in healthy participants cannot be simply extrapolated to patients. Finally, given the potential influence of respiration on postganglionic sympathetic discharge, it would have been desirable to also record and analyze breathing, yet others did not observe effects of ivabradine on respiratory rate either in healthy men<xref rid="jah31274-bib-0036" ref-type="ref">36</xref> or in patients with chronic obstructive pulmonary disease.<xref rid="jah31274-bib-0037" ref-type="ref">37</xref>
</p></sec><sec id="jah31274-sec-0015"><title>Conclusion</title><p>High&#x02010;fidelity physiological phenotyping provides pharmacological insight that could not be gained by routine HR and BP measurements. We observed that HCN4 blockade with ivabradine reduced HR but did not impair sympathetic or parasympathetic baroreflex function. This feature preserves baroreflex&#x02010;dependent buffering of BP changes and aggravates parasympathetically mediated HR reduction; therefore, ivabradine's use dependence is not protective against marked bradycardia. Our results could explain unfavorable responses to ivabradine in recent clinical trials. Moreover, our findings provide a better understanding of HCN4's physiology in humans, which could be applied to elucidate diseases associated with perturbed HR regulation. Excess HCN4 conductivity, for example, could contribute to postural tachycardia syndrome, a condition characterized by sinus tachycardia with standing and a mismatch between cardiac and vascular sympathetic activation.<xref rid="jah31274-bib-0038" ref-type="ref">38</xref>, <xref rid="jah31274-bib-0039" ref-type="ref">39</xref> Indeed, HCN4 inhibition may improve symptoms of postural tachycardia syndrome.<xref rid="jah31274-bib-0040" ref-type="ref">40</xref> Although gain&#x02010;of&#x02010;function mutations in the <italic>HCN4</italic> gene have not been discovered, functional HCN4 gain of function has been described in right atrial samples from patients with chronic atrial fibrillation.<xref rid="jah31274-bib-0041" ref-type="ref">41</xref> Patients with heart failure or coronary artery disease, who are currently being considered for ivabradine treatment, also show redistribution of sympathetic activity toward the heart with an associated increase in HR.<xref rid="jah31274-bib-0042" ref-type="ref">42</xref>, <xref rid="jah31274-bib-0043" ref-type="ref">43</xref>
</p></sec><sec id="jah31274-sec-0017"><title>Sources of Funding</title><p>This study was funded by a grant of the German Research Foundation (Deutsche Forschungsgemeinschaft, DFG) awarded to Jordan (JO 284/8&#x02010;1). Tank, Heusser, and May were funded by a grant of the German Aerospace Center (Deutsches Zentrum f&#x000fc;r Luft&#x02010; und Raumfahrt, DLR, 50 WB1117).</p></sec><sec id="jah31274-sec-0018"><title>Disclosures</title><p>None.</p></sec></body><back><ack id="jah31274-sec-0016"><title>Acknowledgments</title><p>We gratefully acknowledge the contributions of our study nurses Gabriele Rahn, Nadine Kr&#x000fc;ger, Anke Strau&#x000df;, Claudia Kunze, Marion Kliemt, Kristina Johnson, and Ina Groen. We also thank Stefanie Fenske for advice.</p></ack><ref-list content-type="cited-references" id="jah31274-bibl-0001"><title>References</title><ref id="jah31274-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="jah31274-cit-0001">
<string-name>
<surname>Brown</surname>
<given-names>HF</given-names>
</string-name>, <string-name>
<surname>DiFrancesco</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Noble</surname>
<given-names>SJ</given-names>
</string-name>. <article-title>How does adrenaline accelerate the heart?</article-title>
<source>Nature</source>. <year>1979</year>;<volume>280</volume>:<fpage>235</fpage>&#x02013;<lpage>236</lpage>.<pub-id pub-id-type="pmid">450140</pub-id></mixed-citation></ref><ref id="jah31274-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="jah31274-cit-0002">
<string-name>
<surname>DiFrancesco</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Tromba</surname>
<given-names>C</given-names>
</string-name>. <article-title>Muscarinic control of the hyperpolarization&#x02010;activated current (I<sub>f</sub>) in rabbit sino&#x02010;atrial node myocytes</article-title>. <source>J Physiol</source>. <year>1988</year>;<volume>405</volume>:<fpage>493</fpage>&#x02013;<lpage>510</lpage>.<pub-id pub-id-type="pmid">2475609</pub-id></mixed-citation></ref><ref id="jah31274-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="jah31274-cit-0003">
<string-name>
<surname>Schulze&#x02010;Bahr</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Neu</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Friederich</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Kaupp</surname>
<given-names>UB</given-names>
</string-name>, <string-name>
<surname>Breithardt</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Pongs</surname>
<given-names>O</given-names>
</string-name>, <string-name>
<surname>Isbrandt</surname>
<given-names>D</given-names>
</string-name>. <article-title>Pacemaker channel dysfunction in a patient with sinus node disease</article-title>. <source>J Clin Invest</source>. <year>2003</year>;<volume>111</volume>:<fpage>1537</fpage>&#x02013;<lpage>1545</lpage>.<pub-id pub-id-type="pmid">12750403</pub-id></mixed-citation></ref><ref id="jah31274-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="jah31274-cit-0004">
<string-name>
<surname>Harzheim</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Pfeiffer</surname>
<given-names>KH</given-names>
</string-name>, <string-name>
<surname>Fabritz</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Kremmer</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Buch</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Waisman</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Kirchhof</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Kaupp</surname>
<given-names>UB</given-names>
</string-name>, <string-name>
<surname>Seifert</surname>
<given-names>R</given-names>
</string-name>. <article-title>Cardiac pacemaker function of HCN4 channels in mice is confined to embryonic development and requires cyclic AMP</article-title>. <source>EMBO J</source>. <year>2008</year>;<volume>27</volume>:<fpage>692</fpage>&#x02013;<lpage>703</lpage>.<pub-id pub-id-type="pmid">18219271</pub-id></mixed-citation></ref><ref id="jah31274-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="jah31274-cit-0005">
<string-name>
<surname>Doan</surname>
<given-names>TN</given-names>
</string-name>, <string-name>
<surname>Stephans</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Ramirez</surname>
<given-names>AN</given-names>
</string-name>, <string-name>
<surname>Glazebrook</surname>
<given-names>PA</given-names>
</string-name>, <string-name>
<surname>Andresen</surname>
<given-names>MC</given-names>
</string-name>, <string-name>
<surname>Kunze</surname>
<given-names>DL</given-names>
</string-name>. <article-title>Differential distribution and function of hyperpolarization&#x02010;activated channels in sensory neurons and mechanosensitive fibers</article-title>. <source>J Neurosci</source>. <year>2004</year>;<volume>24</volume>:<fpage>3335</fpage>&#x02013;<lpage>3343</lpage>.<pub-id pub-id-type="pmid">15056713</pub-id></mixed-citation></ref><ref id="jah31274-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="jah31274-cit-0006">
<string-name>
<surname>Li</surname>
<given-names>YL</given-names>
</string-name>, <string-name>
<surname>Tran</surname>
<given-names>TP</given-names>
</string-name>, <string-name>
<surname>Muelleman</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Schultz</surname>
<given-names>HD</given-names>
</string-name>. <article-title>Blunted excitability of aortic baroreceptor neurons in diabetic rats: involvement of hyperpolarization&#x02010;activated channel</article-title>. <source>Cardiovasc Res</source>. <year>2008</year>;<volume>79</volume>:<fpage>715</fpage>&#x02013;<lpage>721</lpage>.<pub-id pub-id-type="pmid">18524809</pub-id></mixed-citation></ref><ref id="jah31274-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="jah31274-cit-0007">
<string-name>
<surname>DiFrancesco</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Camm</surname>
<given-names>JA</given-names>
</string-name>. <article-title>Heart rate lowering by specific and selective I(f) current inhibition with ivabradine: a new therapeutic perspective in cardiovascular disease</article-title>. <source>Drugs</source>. <year>2004</year>;<volume>64</volume>:<fpage>1757</fpage>&#x02013;<lpage>1765</lpage>.<pub-id pub-id-type="pmid">15301560</pub-id></mixed-citation></ref><ref id="jah31274-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="jah31274-cit-0008">
<string-name>
<surname>Bucchi</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Baruscotti</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Nardini</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Barbuti</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Micheloni</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Bolognesi</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>DiFrancesco</surname>
<given-names>D</given-names>
</string-name>. <article-title>Identification of the molecular site of ivabradine binding to HCN4 channels</article-title>. <source>PLoS One</source>. <year>2013</year>;<volume>8</volume>:<fpage>e53132</fpage>.<pub-id pub-id-type="pmid">23308150</pub-id></mixed-citation></ref><ref id="jah31274-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="jah31274-cit-0009">
<string-name>
<surname>Swedberg</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Komajda</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Bohm</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Borer</surname>
<given-names>JS</given-names>
</string-name>, <string-name>
<surname>Ford</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Dubost&#x02010;Brama</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Lerebours</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Tavazzi</surname>
<given-names>L</given-names>
</string-name>. <article-title>Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo&#x02010;controlled study</article-title>. <source>Lancet</source>. <year>2010</year>;<volume>376</volume>:<fpage>875</fpage>&#x02013;<lpage>885</lpage>.<pub-id pub-id-type="pmid">20801500</pub-id></mixed-citation></ref><ref id="jah31274-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="jah31274-cit-0010">
<string-name>
<surname>Borer</surname>
<given-names>JS</given-names>
</string-name>, <string-name>
<surname>Fox</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Jaillon</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Lerebours</surname>
<given-names>G</given-names>
</string-name>. <article-title>Antianginal and antiischemic effects of ivabradine, an I(f) inhibitor, in stable angina: a randomized, double&#x02010;blind, multicentered, placebo&#x02010;controlled trial</article-title>. <source>Circulation</source>. <year>2003</year>;<volume>107</volume>:<fpage>817</fpage>&#x02013;<lpage>823</lpage>.<pub-id pub-id-type="pmid">12591750</pub-id></mixed-citation></ref><ref id="jah31274-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="jah31274-cit-0011">
<string-name>
<surname>Schroeder</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Heusser</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Zoerner</surname>
<given-names>AA</given-names>
</string-name>, <string-name>
<surname>Grosshennig</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Wenzel</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>May</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Sweep</surname>
<given-names>FC</given-names>
</string-name>, <string-name>
<surname>Mehling</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Luft</surname>
<given-names>FC</given-names>
</string-name>, <string-name>
<surname>Tank</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Jordan</surname>
<given-names>J</given-names>
</string-name>. <article-title>Pacemaker current inhibition in experimental human cardiac sympathetic activation: a double&#x02010;blind, randomized, crossover study</article-title>. <source>Clin Pharmacol Ther</source>. <year>2014</year>;<volume>95</volume>:<fpage>601</fpage>&#x02013;<lpage>607</lpage>.<pub-id pub-id-type="pmid">24509430</pub-id></mixed-citation></ref><ref id="jah31274-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="jah31274-cit-0012">
<string-name>
<surname>Bucchi</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Baruscotti</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>DiFrancesco</surname>
<given-names>D</given-names>
</string-name>. <article-title>Current&#x02010;dependent block of rabbit sino&#x02010;atrial node I(f) channels by ivabradine</article-title>. <source>J Gen Physiol</source>. <year>2002</year>;<volume>120</volume>:<fpage>1</fpage>&#x02013;<lpage>13</lpage>.<pub-id pub-id-type="pmid">12084770</pub-id></mixed-citation></ref><ref id="jah31274-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="jah31274-cit-0013">
<string-name>
<surname>Courtney</surname>
<given-names>KR</given-names>
</string-name>. <article-title>Mechanism of frequency&#x02010;dependent inhibition of sodium currents in frog myelinated nerve by the lidocaine derivative GEA</article-title>. <source>J Pharmacol Exp Ther</source>. <year>1975</year>;<volume>195</volume>:<fpage>225</fpage>&#x02013;<lpage>236</lpage>.<pub-id pub-id-type="pmid">1081138</pub-id></mixed-citation></ref><ref id="jah31274-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="jah31274-cit-0014">
<string-name>
<surname>DiFrancesco</surname>
<given-names>D</given-names>
</string-name>. <article-title>Cardiac pacemaker I(f) current and its inhibition by heart rate&#x02010;reducing agents</article-title>. <source>Curr Med Res Opin</source>. <year>2005</year>;<volume>21</volume>:<fpage>1115</fpage>&#x02013;<lpage>1122</lpage>.<pub-id pub-id-type="pmid">16004681</pub-id></mixed-citation></ref><ref id="jah31274-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="jah31274-cit-0015">
<string-name>
<surname>Willemsen</surname>
<given-names>JJ</given-names>
</string-name>, <string-name>
<surname>Sweep</surname>
<given-names>CG</given-names>
</string-name>, <string-name>
<surname>Lenders</surname>
<given-names>JW</given-names>
</string-name>, <string-name>
<surname>Ross</surname>
<given-names>HA</given-names>
</string-name>. <article-title>Stability of plasma free metanephrines during collection and storage as assessed by an optimized HPLC method with electrochemical detection</article-title>. <source>Clin Chem</source>. <year>2003</year>;<volume>49</volume>:<fpage>1951</fpage>&#x02013;<lpage>1953</lpage>.<pub-id pub-id-type="pmid">14578334</pub-id></mixed-citation></ref><ref id="jah31274-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="jah31274-cit-0016">
<string-name>
<surname>Tank</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Heusser</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Malehsa</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Hegemann</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Haufe</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Brinkmann</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Tegtbur</surname>
<given-names>U</given-names>
</string-name>, <string-name>
<surname>Diedrich</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Bara</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Jordan</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Struber</surname>
<given-names>M</given-names>
</string-name>. <article-title>Patients with continuous&#x02010;flow left ventricular assist devices provide insight in human baroreflex physiology</article-title>. <source>Hypertension</source>. <year>2012</year>;<volume>60</volume>:<fpage>849</fpage>&#x02013;<lpage>855</lpage>.<pub-id pub-id-type="pmid">22824986</pub-id></mixed-citation></ref><ref id="jah31274-bib-0017"><label>17</label><mixed-citation publication-type="miscellaneous" id="jah31274-cit-0017">
<string-name>
<surname>Dupont</surname>
<given-names>WD</given-names>
</string-name>, <string-name>
<surname>Plummer</surname>
<given-names>WD</given-names>
</string-name> Jr. PS: <article-title>Power and sample size calculation</article-title>. <year>2009</year> Available at: <ext-link ext-link-type="uri" xlink:href="http://biostat.mc.vanderbilt.edu/wiki/Main/PowerSampleSize">http://biostat.mc.vanderbilt.edu/wiki/Main/PowerSampleSize</ext-link>. Accessed January 05, 2016.</mixed-citation></ref><ref id="jah31274-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="jah31274-cit-0018">
<string-name>
<surname>Hills</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Armitage</surname>
<given-names>P</given-names>
</string-name>. <article-title>The two&#x02010;period cross&#x02010;over clinical trial</article-title>. <source>Br J Clin Pharmacol</source>. <year>1979</year>;<volume>8</volume>:<fpage>7</fpage>&#x02013;<lpage>20</lpage>.<pub-id pub-id-type="pmid">552299</pub-id></mixed-citation></ref><ref id="jah31274-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="jah31274-cit-0019">
<string-name>
<surname>Jordan</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Tank</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Shannon</surname>
<given-names>JR</given-names>
</string-name>, <string-name>
<surname>Diedrich</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Lipp</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Schroder</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Arnold</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Sharma</surname>
<given-names>AM</given-names>
</string-name>, <string-name>
<surname>Biaggioni</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Robertson</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Luft</surname>
<given-names>FC</given-names>
</string-name>. <article-title>Baroreflex buffering and susceptibility to vasoactive drugs</article-title>. <source>Circulation</source>. <year>2002</year>;<volume>105</volume>:<fpage>1459</fpage>&#x02013;<lpage>1464</lpage>.<pub-id pub-id-type="pmid">11914255</pub-id></mixed-citation></ref><ref id="jah31274-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="jah31274-cit-0020">
<string-name>
<surname>Nof</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Luria</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Brass</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Marek</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Lahat</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Reznik&#x02010;Wolf</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Pras</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Dascal</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Eldar</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Glikson</surname>
<given-names>M</given-names>
</string-name>. <article-title>Point mutation in the HCN4 cardiac ion channel pore affecting synthesis, trafficking, and functional expression is associated with familial asymptomatic sinus bradycardia</article-title>. <source>Circulation</source>. <year>2007</year>;<volume>116</volume>:<fpage>463</fpage>&#x02013;<lpage>470</lpage>.<pub-id pub-id-type="pmid">17646576</pub-id></mixed-citation></ref><ref id="jah31274-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="jah31274-cit-0021">
<string-name>
<surname>Duhme</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Schweizer</surname>
<given-names>PA</given-names>
</string-name>, <string-name>
<surname>Thomas</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Becker</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Schroter</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Barends</surname>
<given-names>TR</given-names>
</string-name>, <string-name>
<surname>Schlichting</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Draguhn</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Bruehl</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Katus</surname>
<given-names>HA</given-names>
</string-name>, <string-name>
<surname>Koenen</surname>
<given-names>M</given-names>
</string-name>. <article-title>Altered HCN4 channel C&#x02010;linker interaction is associated with familial tachycardia&#x02010;bradycardia syndrome and atrial fibrillation</article-title>. <source>Eur Heart J</source>. <year>2013</year>;<volume>34</volume>:<fpage>2768</fpage>&#x02013;<lpage>2775</lpage>.<pub-id pub-id-type="pmid">23178648</pub-id></mixed-citation></ref><ref id="jah31274-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="jah31274-cit-0022">
<string-name>
<surname>Ueda</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Nakamura</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Hayashi</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Inagaki</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Takahashi</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Arimura</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Morita</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Higashiuesato</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Hirano</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Yasunami</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Takishita</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Yamashina</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Ohe</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Sunamori</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Hiraoka</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Kimura</surname>
<given-names>A</given-names>
</string-name>. <article-title>Functional characterization of a trafficking&#x02010;defective HCN4 mutation, D553N, associated with cardiac arrhythmia</article-title>. <source>J Biol Chem</source>. <year>2004</year>;<volume>279</volume>:<fpage>27194</fpage>&#x02013;<lpage>27198</lpage>.<pub-id pub-id-type="pmid">15123648</pub-id></mixed-citation></ref><ref id="jah31274-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="jah31274-cit-0023">
<string-name>
<surname>Milanesi</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Baruscotti</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Gnecchi&#x02010;Ruscone</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>DiFrancesco</surname>
<given-names>D</given-names>
</string-name>. <article-title>Familial sinus bradycardia associated with a mutation in the cardiac pacemaker channel</article-title>. <source>N Engl J Med</source>. <year>2006</year>;<volume>354</volume>:<fpage>151</fpage>&#x02013;<lpage>157</lpage>.<pub-id pub-id-type="pmid">16407510</pub-id></mixed-citation></ref><ref id="jah31274-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="jah31274-cit-0024">
<string-name>
<surname>Herrmann</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Stieber</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Stockl</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Hofmann</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Ludwig</surname>
<given-names>A</given-names>
</string-name>. <article-title>HCN4 provides a &#x0201c;depolarization reserve&#x0201d; and is not required for heart rate acceleration in mice</article-title>. <source>EMBO J</source>. <year>2007</year>;<volume>26</volume>:<fpage>4423</fpage>&#x02013;<lpage>4432</lpage>.<pub-id pub-id-type="pmid">17914461</pub-id></mixed-citation></ref><ref id="jah31274-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="jah31274-cit-0025">
<string-name>
<surname>Li</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Lines</surname>
<given-names>GT</given-names>
</string-name>, <string-name>
<surname>Maleckar</surname>
<given-names>MM</given-names>
</string-name>, <string-name>
<surname>Tveito</surname>
<given-names>A</given-names>
</string-name>. <article-title>Mathematical models of cardiac pacemaking function</article-title>. <source>Front Phys</source>. <year>2013</year>;<volume>1</volume>:<fpage>1</fpage>&#x02013;<lpage>13</lpage>.</mixed-citation></ref><ref id="jah31274-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="jah31274-cit-0026">
<string-name>
<surname>Yaniv</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Maltsev</surname>
<given-names>VA</given-names>
</string-name>. <article-title>Numerical modeling calcium and CaMKII effects in the SA node</article-title>. <source>Front Pharmacol</source>. <year>2014</year>;<volume>5</volume>:<fpage>58</fpage>.<pub-id pub-id-type="pmid">24744732</pub-id></mixed-citation></ref><ref id="jah31274-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="jah31274-cit-0027">
<string-name>
<surname>Kurata</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Matsuda</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Hisatome</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Shibamoto</surname>
<given-names>T</given-names>
</string-name>. <article-title>Roles of hyperpolarization&#x02010;activated current If in sinoatrial node pacemaking: insights from bifurcation analysis of mathematical models</article-title>. <source>Am J Physiol Heart Circ Physiol</source>. <year>2010</year>;<volume>298</volume>:<fpage>H1748</fpage>&#x02013;<lpage>H1760</lpage>.<pub-id pub-id-type="pmid">20363885</pub-id></mixed-citation></ref><ref id="jah31274-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="jah31274-cit-0028">
<string-name>
<surname>Fox</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Ford</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Steg</surname>
<given-names>PG</given-names>
</string-name>, <string-name>
<surname>Tardif</surname>
<given-names>JC</given-names>
</string-name>, <string-name>
<surname>Tendera</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Ferrari</surname>
<given-names>R</given-names>
</string-name>. <article-title>Ivabradine in stable coronary artery disease without clinical heart failure</article-title>. <source>N Engl J Med</source>. <year>2014</year>;<volume>371</volume>:<fpage>1091</fpage>&#x02013;<lpage>1099</lpage>.<pub-id pub-id-type="pmid">25176136</pub-id></mixed-citation></ref><ref id="jah31274-bib-0029"><label>29</label><mixed-citation publication-type="journal" id="jah31274-cit-0029">
<string-name>
<surname>Tank</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Heusser</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Diedrich</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Luft</surname>
<given-names>FC</given-names>
</string-name>, <string-name>
<surname>Jordan</surname>
<given-names>J</given-names>
</string-name>. <article-title>A novel pharmacological approach to determining parasympathetic heart rate reserve in human subjects</article-title>. <source>Clin Pharmacol Ther</source>. <year>2010</year>;<volume>88</volume>:<fpage>630</fpage>&#x02013;<lpage>633</lpage>.<pub-id pub-id-type="pmid">20861836</pub-id></mixed-citation></ref><ref id="jah31274-bib-0030"><label>30</label><mixed-citation publication-type="journal" id="jah31274-cit-0030">
<string-name>
<surname>Ragueneau</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Laveille</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Jochemsen</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Resplandy</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Funck&#x02010;Brentano</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Jaillon</surname>
<given-names>P</given-names>
</string-name>. <article-title>Pharmacokinetic&#x02010;pharmacodynamic modeling of the effects of ivabradine, a direct sinus node inhibitor, on heart rate in healthy volunteers</article-title>. <source>Clin Pharmacol Ther</source>. <year>1998</year>;<volume>64</volume>:<fpage>192</fpage>&#x02013;<lpage>203</lpage>.<pub-id pub-id-type="pmid">9728900</pub-id></mixed-citation></ref><ref id="jah31274-bib-0031"><label>31</label><mixed-citation publication-type="journal" id="jah31274-cit-0031">
<string-name>
<surname>Seifert</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Scholten</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Gauss</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Mincheva</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Lichter</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Kaupp</surname>
<given-names>UB</given-names>
</string-name>. <article-title>Molecular characterization of a slowly gating human hyperpolarization&#x02010;activated channel predominantly expressed in thalamus, heart, and testis</article-title>. <source>Proc Natl Acad Sci USA</source>. <year>1999</year>;<volume>96</volume>:<fpage>9391</fpage>&#x02013;<lpage>9396</lpage>.<pub-id pub-id-type="pmid">10430953</pub-id></mixed-citation></ref><ref id="jah31274-bib-0032"><label>32</label><mixed-citation publication-type="journal" id="jah31274-cit-0032">
<string-name>
<surname>Hughes</surname>
<given-names>DI</given-names>
</string-name>, <string-name>
<surname>Boyle</surname>
<given-names>KA</given-names>
</string-name>, <string-name>
<surname>Kinnon</surname>
<given-names>CM</given-names>
</string-name>, <string-name>
<surname>Bilsland</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Quayle</surname>
<given-names>JA</given-names>
</string-name>, <string-name>
<surname>Callister</surname>
<given-names>RJ</given-names>
</string-name>, <string-name>
<surname>Graham</surname>
<given-names>BA</given-names>
</string-name>. <article-title>HCN4 subunit expression in fast&#x02010;spiking interneurons of the rat spinal cord and hippocampus</article-title>. <source>Neuroscience</source>. <year>2013</year>;<volume>237</volume>:<fpage>7</fpage>&#x02013;<lpage>18</lpage>.<pub-id pub-id-type="pmid">23357121</pub-id></mixed-citation></ref><ref id="jah31274-bib-0033"><label>33</label><mixed-citation publication-type="journal" id="jah31274-cit-0033">
<string-name>
<surname>Tank</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Diedrich</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Szczech</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Luft</surname>
<given-names>FC</given-names>
</string-name>, <string-name>
<surname>Jordan</surname>
<given-names>J</given-names>
</string-name>. <article-title>Alpha&#x02010;2 adrenergic transmission and human baroreflex regulation</article-title>. <source>Hypertension</source>. <year>2004</year>;<volume>43</volume>:<fpage>1035</fpage>&#x02013;<lpage>1041</lpage>.<pub-id pub-id-type="pmid">15037555</pub-id></mixed-citation></ref><ref id="jah31274-bib-0034"><label>34</label><mixed-citation publication-type="journal" id="jah31274-cit-0034">
<string-name>
<surname>Tank</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Schroeder</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Diedrich</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Szczech</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Haertter</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Sharma</surname>
<given-names>AM</given-names>
</string-name>, <string-name>
<surname>Luft</surname>&#x000a0;<given-names>FC</given-names>
</string-name>, <string-name>
<surname>Jordan</surname>
<given-names>J</given-names>
</string-name>. <article-title>Selective impairment in sympathetic vasomotor control with norepinephrine transporter inhibition</article-title>. <source>Circulation</source>. <year>2003</year>;<volume>107</volume>:<fpage>2949</fpage>&#x02013;<lpage>2954</lpage>.<pub-id pub-id-type="pmid">12796139</pub-id></mixed-citation></ref><ref id="jah31274-bib-0035"><label>35</label><mixed-citation publication-type="journal" id="jah31274-cit-0035">
<string-name>
<surname>Heusser</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Tank</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Diedrich</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Engeli</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Klaua</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Kruger</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Strauss</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Stoffels</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Luft</surname>
<given-names>FC</given-names>
</string-name>, <string-name>
<surname>Jordan</surname>
<given-names>J</given-names>
</string-name>. <article-title>Influence of sibutramine treatment on sympathetic vasomotor tone in obese subjects</article-title>. <source>Clin Pharmacol Ther</source>. <year>2006</year>;<volume>79</volume>:<fpage>500</fpage>&#x02013;<lpage>508</lpage>.<pub-id pub-id-type="pmid">16678551</pub-id></mixed-citation></ref><ref id="jah31274-bib-0036"><label>36</label><mixed-citation publication-type="journal" id="jah31274-cit-0036">
<string-name>
<surname>Jiang</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Tian</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Huang</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Xu</surname>
<given-names>L</given-names>
</string-name>. <article-title>Pharmacokinetic and safety profile of ivabradine in healthy Chinese men: a phase I, randomized, open&#x02010;label, increasing single&#x02010; and multiple&#x02010;dose study</article-title>. <source>Clin Ther</source>. <year>2013</year>;<volume>35</volume>:<fpage>1933</fpage>&#x02013;<lpage>1945</lpage>.<pub-id pub-id-type="pmid">24332196</pub-id></mixed-citation></ref><ref id="jah31274-bib-0037"><label>37</label><mixed-citation publication-type="journal" id="jah31274-cit-0037">
<string-name>
<surname>Komlev</surname>
<given-names>AD</given-names>
</string-name>, <string-name>
<surname>Kuziaev</surname>
<given-names>AI</given-names>
</string-name>, <string-name>
<surname>Laskin</surname>
<given-names>GM</given-names>
</string-name>, <string-name>
<surname>Kuzenkova</surname>
<given-names>VE</given-names>
</string-name>, <string-name>
<surname>Kolosova</surname>
<given-names>MV</given-names>
</string-name>. <article-title>Effect of the I(f) channel blocker ivabradine on the parameters of external respiration function in patients with chronic obstructive pulmonary disease in its stable course period</article-title>. <source>Ter Arkh</source>. <year>2010</year>;<volume>82</volume>:<fpage>23</fpage>&#x02013;<lpage>25</lpage>.<pub-id pub-id-type="pmid">20564916</pub-id></mixed-citation></ref><ref id="jah31274-bib-0038"><label>38</label><mixed-citation publication-type="journal" id="jah31274-cit-0038">
<string-name>
<surname>Jacob</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Costa</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Shannon</surname>
<given-names>JR</given-names>
</string-name>, <string-name>
<surname>Robertson</surname>
<given-names>RM</given-names>
</string-name>, <string-name>
<surname>Wathen</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Stein</surname>
<given-names>CM</given-names>
</string-name>, <string-name>
<surname>Biaggioni</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Ertl</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Black</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Robertson</surname>
<given-names>D</given-names>
</string-name>. <article-title>The neuropathic postural tachycardia syndrome</article-title>. <source>N Engl J Med</source>. <year>2000</year>;<volume>343</volume>:<fpage>1008</fpage>&#x02013;<lpage>1014</lpage>.<pub-id pub-id-type="pmid">11018167</pub-id></mixed-citation></ref><ref id="jah31274-bib-0039"><label>39</label><mixed-citation publication-type="journal" id="jah31274-cit-0039">
<string-name>
<surname>Furlan</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Jacob</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Snell</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Robertson</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Porta</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Harris</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Mosqueda&#x02010;Garcia</surname>
<given-names>R</given-names>
</string-name>. <article-title>Chronic orthostatic intolerance: a disorder with discordant cardiac and vascular sympathetic control</article-title>. <source>Circulation</source>. <year>1998</year>;<volume>98</volume>:<fpage>2154</fpage>&#x02013;<lpage>2159</lpage>.<pub-id pub-id-type="pmid">9815870</pub-id></mixed-citation></ref><ref id="jah31274-bib-0040"><label>40</label><mixed-citation publication-type="journal" id="jah31274-cit-0040">
<string-name>
<surname>McDonald</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Frith</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Newton</surname>
<given-names>JL</given-names>
</string-name>. <article-title>Single centre experience of ivabradine in postural orthostatic tachycardia syndrome</article-title>. <source>Europace</source>. <year>2011</year>;<volume>13</volume>:<fpage>427</fpage>&#x02013;<lpage>430</lpage>.<pub-id pub-id-type="pmid">21062792</pub-id></mixed-citation></ref><ref id="jah31274-bib-0041"><label>41</label><mixed-citation publication-type="journal" id="jah31274-cit-0041">
<string-name>
<surname>Stillitano</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Lonardo</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Giunti</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Del</surname>
<given-names>LM</given-names>
</string-name>, <string-name>
<surname>Coppini</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Spinelli</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Sartiani</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Poggesi</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Mugelli</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Cerbai</surname>
<given-names>E</given-names>
</string-name>. <article-title>Chronic atrial fibrillation alters the functional properties of If in the human atrium</article-title>. <source>J Cardiovasc Electrophysiol</source>. <year>2013</year>;<volume>24</volume>:<fpage>1391</fpage>&#x02013;<lpage>1400</lpage>.<pub-id pub-id-type="pmid">23869794</pub-id></mixed-citation></ref><ref id="jah31274-bib-0042"><label>42</label><mixed-citation publication-type="journal" id="jah31274-cit-0042">
<string-name>
<surname>Kaye</surname>
<given-names>DM</given-names>
</string-name>, <string-name>
<surname>Lefkovits</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Jennings</surname>
<given-names>GL</given-names>
</string-name>, <string-name>
<surname>Bergin</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Broughton</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Esler</surname>
<given-names>MD</given-names>
</string-name>. <article-title>Adverse consequences of high sympathetic nervous activity in the failing human heart</article-title>. <source>J Am Coll Cardiol</source>. <year>1995</year>;<volume>26</volume>:<fpage>1257</fpage>&#x02013;<lpage>1263</lpage>.<pub-id pub-id-type="pmid">7594040</pub-id></mixed-citation></ref><ref id="jah31274-bib-0043"><label>43</label><mixed-citation publication-type="journal" id="jah31274-cit-0043">
<string-name>
<surname>McCance</surname>
<given-names>AJ</given-names>
</string-name>, <string-name>
<surname>Thompson</surname>
<given-names>PA</given-names>
</string-name>, <string-name>
<surname>Forfar</surname>
<given-names>JC</given-names>
</string-name>. <article-title>Increased cardiac sympathetic nervous activity in patients with unstable coronary heart disease</article-title>. <source>Eur Heart J</source>. <year>1993</year>;<volume>14</volume>:<fpage>751</fpage>&#x02013;<lpage>757</lpage>.<pub-id pub-id-type="pmid">8325300</pub-id></mixed-citation></ref></ref-list></back></article>